Novo Nordisk A/S (NVO)

NYQ – Real Time Price. Currency in USD

48.07

+0.43 (0.90%)

At close: Jun 26, 2026, 4:05 PM EDT

48.01

-0.06 (-0.12%)

After-hours: Jun 26, 2026, 7:59 PM EDT

16.06.2026

Hacking group claims major hack of Novo Nordisk and attempted $25 million extortion

A cyber extortion group claimed on Tuesday to have stolen more than a terabyte of data from pharmaceutical ‌giant Novo Nordisk and said it is exploring selling parts of the data after unsuccessfully demanding $25 million from the company.

16.06.2026

Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock?

Eli Lilly currently leads the weight loss market. Novo Nordisk's newer launches could help it make up some ground.

16.06.2026

Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

16.06.2026

Novo Nordisk: I Was Fooled By The Market Again (Rating Upgrade)

Novo Nordisk has significantly regained the market's confidence as the Wegovy pill drives notable recovery and market share stabilization. NVO's international operations offset U.S. pricing pressures, with oral GLP-1 demand proving additive rather than cannibalistic to injectables. Despite a projected 7% sales decline in 2024, NVO maintains robust 41%+ operating margins and trades at historically low 14.1x earnings.

16.06.2026

Novo Nordisk to seek regulatory approval for Wegovy pill in China soon, says CEO

Novo Nordisk plans ‌to seek Chinese regulatory approval for its ⁠weight-loss pill "very soon," CEO Mike Doustdar said Tuesday, in a move ‌to ⁠catch up with rival Eli Lilly ⁠in the world's second-largest ⁠pharmaceutical market.

15.06.2026

How LLY Overtook NVO in GLP-1 Space & Offering LLY Options Trade

The GLP-1 race "is not fair to call a race anymore," argues Scott Zari when comparing Eli Lilly (LLY) and Novo Nordisk (NVO), calling the former a clear winner. He explains how Eli Lilly pulled ahead in the market and ways it's bolstering healthcare offerings in ways he sees Novo Nordisk lagging.

15.06.2026

Novo Nordisk Gains 7% in a Week: How Should Investors Play the Stock?

NVO stock jumps 7% in a week on U.K. approval of oral Wegovy and positive commercial updates, but competition and 2026 pressure cloud near-term outlook.

Videos

15.06.2026

Positive

How LLY Overtook NVO in GLP-1 Space & Offering LLY Options Trade

13.06.2026

Neutral

The Next Phase Of The Obesity Drug Race

09.06.2026

Positive

Novo Nordisk CEO: '80% of Wegovy pill customers' have never taken a GLP-1 before

09.06.2026

Positive

Novo Nordisk CEO: 'Common sense' should drive seniors on Medicare to opt for Wegovy

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
NVO	Wolfe Research	Peer Perform	undefined >> undefined	March 26th 2026
NVO	Bernstein	Outperform	undefined >> $175	March 18th 2026
NVO	TD Cowen	Hold	undefined >> $42	March 10th 2026
NVO	Morgan Stanley	Equal Weight	undefined >> $40	March 3rd 2026
NVO	Goldman	Neutral	undefined >> $41	March 2nd 2026
NVO	JP Morgan	Neutral	undefined >> undefined	February 24th 2026
NVO	Kepler	Hold	undefined >> undefined	February 24th 2026
NVO	Deutsche Bank	Hold	undefined >> undefined	February 23rd 2026

Press releases

11.06.2026

Novo Nordisk A/S: IT Security incident at Novo Nordisk

Bagsværd, Denmark, 11 June 2026 – Novo Nordisk A/S has identified an IT security incident involving unauthorised access to a limited number of internal IT systems. Upon learning of the incident, we launched an investigation with the assistance of external cybersecurity experts, and we are in contact with the relevant authorities.

11.06.2026

Novo Nordisk: Wegovy® pill (semaglutide tablets) becomes first daily GLP-1 weight-loss pill approved in the UK

Approval is based on results from the OASIS 4 trial, which investigated semaglutide tablets 25 mg in adults living with obesity and overweight versus placebo in addition to diet and exercise Semaglutide tablets will be available as a once-daily treatment, an alternative to weekly injections for adults living with obesity or overweight with a weight-related condition, alongside diet and exercise After this approval from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), Novo Nordisk anticipates Wegovy® pill will be available via private prescription within weeks Bagsværd, Denmark, 11 June 2026 – Wegovy® pill, the new daily weight management tablet, has been approved in the UK as an adjunct to a reduced-calorie diet and increased physical activity, offering a first-of-its-kind alternative to injectable treatments for adults. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Wegovy® pill (semaglutide tablets), an oral glucagon-like peptide-1 (GLP-1) receptor agonist licensed for weight management in adults living with obesity (initial Body Mass Index (BMI) ≥30 kg/m2), or overweight (BMI ≥27 kg/m2 to

08.06.2026

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 8 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026.

03.06.2026

Wegovy® pill launches in the UAE as Novo Nordisk expands global access to obesity care

Novo Nordisk is launching Wegovy® pill in the UAE, the first country outside the US, to make the Wegovy® pill available to people living with obesity

Novo Nordisk A/S (NVO)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Novo Nordisk A/S (NVO)

Hacking group claims major hack of Novo Nordisk and attempted $25 million extortion

Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock?

Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know

Novo Nordisk: I Was Fooled By The Market Again (Rating Upgrade)

Novo Nordisk to seek regulatory approval for Wegovy pill in China soon, says CEO

How LLY Overtook NVO in GLP-1 Space & Offering LLY Options Trade